Improving the outcomes of secondary CNS lymphoma with high-dose thiotepa, busulfan, melphalan, rituximab conditioning and autotransplant.

MLA

Puckrin, Robert, et al. “Improving the Outcomes of Secondary CNS Lymphoma with High-Dose Thiotepa, Busulfan, Melphalan, Rituximab Conditioning and Autotransplant.” Leukemia & Lymphoma, vol. 63, no. 10, Oct. 2022, pp. 2444–52. EBSCOhost, https://doi.org/10.1080/10428194.2022.2068005.

APA

Puckrin, R., Chua, N., Shafey, M., & Stewart, D. A. (2022). Improving the outcomes of secondary CNS lymphoma with high-dose thiotepa, busulfan, melphalan, rituximab conditioning and autotransplant. Leukemia & Lymphoma, 63(10), 2444–2452. https://doi.org/10.1080/10428194.2022.2068005

Chicago

Puckrin, Robert, Neil Chua, Mona Shafey, and Douglas A. Stewart. 2022. “Improving the Outcomes of Secondary CNS Lymphoma with High-Dose Thiotepa, Busulfan, Melphalan, Rituximab Conditioning and Autotransplant.” Leukemia & Lymphoma 63 (10): 2444–52. doi:10.1080/10428194.2022.2068005.